Table 1.

Staging and treatment guidelines for Kaposi sarcoma

ACTG Staging Classification(19)
Characteristic	Good Risk (all of the following)		Poor Risk (any of the following)
Tumor (T)	Tumor confined to skin and/or lymph nodes and/or minimal oral disease		Tumor associated edema or ulceration; extensive oral KS; GI KS; KS in other non-nodal viscera
Immune system (I)	CD4+ cells >=150/microL		CD4+ cells <150microL
Systemic illness	No history of opportunistic infection or thrush; no systemic B symptoms; performance status >= 70 Karnofsky Performance Status		History of opportunistic infection and/or thrush; B symptom; performance status <70 Karnofsky Performance Status; other HIV-related illness (eg, neurologic disease, lymphoma)
WHO KS Treatment Guidelines(16)
Mild/moderate Kaposi sarcoma: ART alone		Severe symptomatic Kaposi sarcoma: ART plus systemic chemotherapy
• Confined to skin and/or lymph   nodes  • No symptomatic visceral disease  • No significant oral disease (does   not interfere with chewing or   swallowing)  • No significant edema affecting   function  • Not functionally disabling or   immediately life-threatening		• Symptomatic visceral disease  • Extensive KS lesions which   interfere with chewing or   swallowing  • Painful or disabling tumor-   associated facial/gential/peripheral   edema or ulcerated tumors  • Life threatening or functionally   disabling disease  • Progressive or persistent KS despite   ART